Drug Interactions between Obegyn and odevixibat

ADJUST DOSING INTERVAL: Concomitant use of some oral medications may reduce the bioavailability of orally administered iron, and vice versa.

Food taken in conjunction with oral iron supplements may reduce the bioavailability of the iron. However, in many patients intolerable gastrointestinal side effects occur necessitating administration with food.

MANAGEMENT: Ideally, iron products should be taken on an empty stomach (i.e., at least 1 hour before or 2 hours after meals), but if this is not possible, administer with meals and monitor the patient more closely for a subtherapeutic effect. Some studies suggest administration of iron with ascorbic acid may enhance bioavailability. In addition, administration of oral iron products and some oral medications should be separated whenever the bioavailability of either agent may be decreased. Consult the product labeling for specific separation times and monitor clinical responses as appropriate.

Switch to consumer interaction data

MONITOR: Odevixibat may affect absorption of fat-soluble vitamins (FSV) including vitamin A, D, E, and K. In clinical studies, new onset or worsening of existing FSV deficiency was reported in 5% of placebo-treated patients, and in 16% of odevixibat-treated 120 mcg/kg/day patients. However, none of the odevixibat-treated 40 mcg/kg/day patients had new onset or worsening of existing FSV deficiency.

MANAGEMENT: Clinical and laboratory monitoring of FSV levels is recommended at baseline and during treatment with odevixibat. If FSV deficiency is diagnosed, supplement with FSV. Odevixibat should be discontinued if FSV deficiency persists or worsens despite adequate FSV supplementation.

Switch to consumer interaction data